PRKCSH Antibody

What is PRKCSH and why is it important in biological research?

PRKCSH, also known as Glucosidase II beta subunit (GluIIβ), functions as a crucial component of the endoplasmic reticulum (ER) quality control system for N-linked glycosylation. It plays an essential role in identifying and eliminating misfolded proteins within the cell . The protein consists of 528 amino acid residues with a molecular mass of approximately 59.4 kilodaltons and exists in two distinct isoforms . PRKCSH contains several functionally significant domains including a leader sequence, an LDLa domain, two EF-hand domains (suggesting calcium-binding properties), and a conserved C-terminal HDEL sequence .

Its importance in research has grown significantly as studies have revealed its involvement in intracellular signal transduction, liver development, and notably, its potential role as an oncogene in various cancer types . The protein's widespread expression across tissues and its localization primarily in the ER make it a subject of interest for researchers investigating fundamental cellular processes and disease mechanisms .

What detection methods are available for PRKCSH in research applications?

Several methodological approaches exist for detecting PRKCSH in biological samples:

• Antibody-based detection methods:

  • Western blotting - For protein expression quantification and molecular weight confirmation

  • Immunohistochemistry (IHC) - For tissue localization studies

  • Immunocytochemistry (ICC) - For cellular localization analysis

  • Immunofluorescence (IF) - For high-resolution subcellular localization

  • ELISA - For quantitative detection in solution-phase samples

• Nucleic acid-based detection:

  • RT-PCR - For mRNA expression analysis

  • Northern blotting - For tissue-specific expression profiling

The sandwich enzyme immunoassay technique is commonly employed in ELISA kits for PRKCSH quantification, with a typical detection range of 0.79-50 ng/mL and sensitivity below 0.39 ng/mL . This technique utilizes an antibody specific for human PRKCSH pre-coated onto a microplate, followed by sample addition, detection antibody binding, and signal development through enzyme conjugation and substrate reaction .

How is PRKCSH expression altered in pathological conditions?

PRKCSH expression demonstrates significant alterations across various pathological conditions:

These expression patterns highlight PRKCSH's potential value as both a prognostic marker and therapeutic target across multiple disease contexts .

What are the optimal conditions for using PRKCSH antibodies in Western blotting applications?

When designing Western blot protocols for PRKCSH detection, researchers should consider the following methodology:

• Sample preparation:

  • For cell/tissue lysates: Use RIPA buffer with protease inhibitors

  • Protein concentration: Load 20-50 μg of total protein per lane

  • Denaturation: Heat samples at 95°C for 5 minutes in reducing conditions

• Electrophoresis parameters:

  • Gel percentage: 10-12% SDS-PAGE gels provide optimal resolution for the 59.4 kDa PRKCSH protein

  • Running conditions: 100-120V for 1-2 hours

• Transfer considerations:

  • PVDF membranes are preferable due to their protein binding capacity

  • Semi-dry transfer: 15V for 30-45 minutes

  • Wet transfer: 100V for 1 hour at 4°C

• Blocking and antibody incubation:

  • Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

  • Primary antibody dilution: Typically 1:500-1:2000 (optimize based on specific antibody)

  • Incubation: Overnight at 4°C with gentle agitation

  • Secondary antibody: Species-appropriate HRP-conjugated at 1:5000-1:10000 dilution

• Detection controls:

  • Positive control: Liver tissue lysate (high endogenous expression)

  • Loading control: GAPDH or β-actin

  • Negative control: Primary antibody omission

The expected band should appear at approximately 59-60 kDa, with potential variation based on post-translational modifications . Researchers should validate antibody specificity using known positive and negative controls to ensure accurate interpretation of results.

How can researchers effectively study PRKCSH's role in N-linked glycosylation processes?

Investigating PRKCSH's function in N-linked glycosylation requires specialized methodological approaches:

• Enzymatic activity assays:

  • Measure Glucosidase II activity using fluorogenic substrates

  • Compare wild-type vs. PRKCSH-depleted conditions to assess its regulatory role

• Glycoprotein profiling techniques:

  • Lectin blotting to detect changes in glycosylation patterns

  • Mass spectrometry-based glycomics to identify specific N-glycan structures affected

  • Pulse-chase experiments with radiolabeled sugars to track glycoprotein maturation kinetics

• Protein-protein interaction studies:

  • Co-immunoprecipitation to confirm PRKCSH interaction with the catalytic alpha subunit (GluIIα)

  • Proximity ligation assays to visualize interactions in situ

  • FRET/BRET approaches for real-time interaction dynamics

• ER stress response analysis:

  • Monitor UPR markers (BiP, CHOP, XBP1 splicing) in PRKCSH-manipulated systems

  • Assess ER retention of glycoproteins using subcellular fractionation and immunoblotting

• Genetic manipulation strategies:

  • CRISPR/Cas9-mediated knockout/knockin

  • Domain-specific mutations to disrupt particular functions

  • Rescue experiments with wild-type or mutant PRKCSH

This integrated approach allows researchers to comprehensively characterize PRKCSH's contribution to the N-linked glycosylation quality control system and its downstream effects on protein folding and secretion .

What considerations are important for studying PRKCSH translocation in response to growth factors?

PRKCSH demonstrates dynamic subcellular localization in response to growth factor stimulation, particularly translocation to the nucleus following acidic fibroblast growth factor (aFGF/FGF-1) treatment and membrane translocation after phosphorylation induced by basic fibroblast growth factor (bFGF/FGF-2) . When investigating these phenomena, researchers should implement the following experimental design elements:

• Growth factor stimulation protocols:

  • Serum starvation: 16-24 hours prior to stimulation

  • FGF-1 concentration: 10-50 ng/mL

  • FGF-2 concentration: 5-20 ng/mL

  • Time course: Assess translocation at multiple timepoints (5, 15, 30, 60, 120 minutes)

• Subcellular fractionation methods:

  • Nuclear/cytoplasmic separation using NE-PER or similar kits

  • Membrane/cytosol fractionation with ultracentrifugation

  • Validate fraction purity with compartment-specific markers:

    • Nuclear: Lamin B, Histone H3

    • Cytoplasmic: GAPDH, α-tubulin

    • Membrane: Na+/K+ ATPase, calnexin

• Live-cell imaging approaches:

  • PRKCSH-GFP fusion proteins for real-time visualization

  • Photoactivatable or photoconvertible tags to track protein movement

  • FRAP (Fluorescence Recovery After Photobleaching) to measure mobility kinetics

• Phosphorylation analysis:

  • Phospho-specific antibodies if phosphorylation sites are known

  • Phos-tag SDS-PAGE to separate phosphorylated from non-phosphorylated forms

  • Mass spectrometry to identify specific phosphorylation sites

• Inhibitor studies:

  • FGF receptor inhibitors to confirm pathway specificity

  • Nuclear transport inhibitors to validate translocation mechanisms

  • Kinase inhibitor panels to identify responsible phosphorylating enzymes

These approaches enable detailed characterization of the regulatory mechanisms governing PRKCSH's subcellular distribution and its growth factor-dependent functions beyond its classical ER localization .

How can researchers address specificity issues with PRKCSH antibodies?

When encountering specificity challenges with PRKCSH antibodies, implement the following troubleshooting strategies:

• Antibody validation methods:

  • PRKCSH knockdown/knockout controls to confirm band specificity

  • Peptide competition assays to verify epitope-specific binding

  • Multiple antibodies targeting different epitopes to corroborate results

  • Testing across multiple cell/tissue types with known expression levels

• Optimizing experimental conditions:

  • Adjusting antibody concentration (titration series)

  • Modifying blocking agents (switch between milk, BSA, or commercial blockers)

  • Altering incubation temperature and duration

  • Increasing washing stringency (higher detergent concentration)

• Cross-reactivity assessment:

  • Review known PRKCSH isoforms and related proteins

  • Test antibodies against recombinant PRKCSH variants

  • Consider species-specific differences if working with non-human models

• Technical considerations for specific applications:

  • Western blot: Use gradient gels to better resolve similar molecular weight proteins

  • IHC/ICC: Include antigen retrieval optimization steps

  • IF: Implement super-resolution techniques for improved specificity determination

  • ELISA: Test for hook effects at high antigen concentrations

Current commercial antibodies show varying degrees of specificity, and researchers should perform application-specific validation before proceeding with critical experiments .

What are the technical challenges in measuring PRKCSH expression in cancer tissues?

Researchers face several methodological challenges when assessing PRKCSH expression in cancer tissues:

• Tissue heterogeneity considerations:

  • Microdissection techniques to isolate tumor cells from stroma

  • Single-cell approaches to resolve expression at cellular resolution

  • Digital spatial profiling for region-specific quantification

• Reference standardization issues:

  • Selection of appropriate normal tissue controls

  • Normalization strategies for quantitative comparisons

  • Internal reference standards for cross-sample consistency

• Expression detection methods:

  • RNA vs. protein level quantification disparities

  • Isoform-specific detection challenges

  • Post-translational modification impacts on antibody recognition

• Technical artifacts and solutions:

  • Fixation effects on epitope accessibility in FFPE samples

    • Extended antigen retrieval protocols

    • Alternative fixation methods assessment

  • Autofluorescence in cancer tissues

    • Spectral unmixing techniques

    • Tissue preparation modifications

• Data interpretation frameworks:

  • Correlation with clinicopathological parameters

  • Integration with other molecular markers

  • Cutoff determination for high vs. low expression

Studies across multiple cancer types have revealed significant PRKCSH overexpression compared to normal tissues, making accurate quantification essential for prognostic applications . Researchers should implement consistent methodologies across samples for valid comparative analyses.

What quality control parameters should be monitored when using PRKCSH ELISA kits?

When utilizing ELISA for PRKCSH quantification, researchers should monitor the following quality control parameters:

Additional quality control considerations include:

• Procedural verification:

  • Maintain consistent incubation times (2h for sample, 1h for detection antibody, 1h for HRP conjugate, 15-20 min for substrate)

  • Ensure uniform temperature control (37°C)

  • Verify complete washing between steps (3x)

• Sample handling precautions:

  • Avoid repeated freeze-thaw cycles

  • Process samples consistently across experiments

  • Consider protease inhibitor addition for labile samples

• Cross-reactivity monitoring:

  • Test with known similar proteins to assess specificity

  • Validate results with alternative detection methods

Commercial PRKCSH ELISA kits typically demonstrate high sensitivity and excellent specificity, though potential cross-reactivity with related proteins cannot be completely excluded . Adherence to these quality control parameters ensures reliable and reproducible quantification of PRKCSH across experimental conditions.

How can PRKCSH be effectively targeted in cancer immunotherapy research?

PRKCSH has emerged as a potential immunotherapeutic target due to its role in modulating anti-tumor immunity, with evidence that its suppression can enhance natural killer (NK) cell and T cell activity . Researchers investigating PRKCSH in cancer immunotherapy should consider these methodological approaches:

• Immune cell interaction studies:

  • Co-culture systems with PRKCSH-modulated cancer cells and immune effectors

  • Transwell assays to distinguish contact-dependent vs. secreted factor effects

  • CyTOF/mass cytometry for comprehensive immune phenotyping

  • Cytotoxicity assays to measure functional killing capacity

• Mechanism investigation techniques:

  • Immune checkpoint molecule expression analysis

  • Cytokine/chemokine profiling in PRKCSH-manipulated environments

  • HLA/antigen presentation pathway assessment

  • Secretome analysis of PRKCSH-modulated cancer cells

• Therapeutic targeting strategies:

  • PRKCSH-directed antibodies with blocking function

  • siRNA/shRNA delivery systems for in vivo knockdown

  • Small molecule inhibitors of PRKCSH function

  • CRISPR-based approaches for precise genetic modulation

• Combination therapy design:

  • PRKCSH targeting with existing immune checkpoint inhibitors

  • Integration with conventional cancer therapies (radiation, chemotherapy)

  • Synergy testing with other glycosylation modifiers

• Biomarker development framework:

  • Correlation of PRKCSH expression with immunotherapy response

  • Development of companion diagnostics for patient stratification

  • Monitoring changes in PRKCSH as a response indicator

The significant correlations between PRKCSH expression and tumor mutational burden (TMB) in five cancer categories, as well as microsatellite instability (MSI) in eight cancer types, further support its potential relevance to immunotherapy response prediction . These parameters are established biomarkers for immunotherapy efficacy, suggesting PRKCSH may serve as an additional predictive indicator.

What experimental approaches are recommended for studying PRKCSH's role in epithelial-mesenchymal transition?

Alternative splicing generates distinct PRKCSH isoforms that influence epithelial-mesenchymal transition (EMT) in cancer progression . To investigate this relationship, researchers should implement the following experimental design:

• Isoform-specific manipulation strategies:

  • Isoform-selective knockdown using targeted siRNAs

  • Overexpression of individual isoforms with epitope tags

  • CRISPR-mediated isoform editing to alter splicing patterns

  • Minigene constructs to study splicing regulation

• EMT marker assessment methods:

  • Protein panel analysis: E-cadherin, N-cadherin, vimentin, ZO-1, Snail, Slug, Twist

  • mRNA expression profiling of EMT-associated transcription factors

  • Migration/invasion functional assays:

    • Wound healing assays

    • Transwell migration and invasion assays

    • 3D spheroid invasion models

  • Morphological characterization with quantitative image analysis

• Mechanistic investigation approaches:

  • Splicing factor identification through RNA-protein pulldowns

  • Signaling pathway analysis (TGF-β, Wnt, Notch)

  • Glycosylation status of EMT-associated proteins

  • Chromatin immunoprecipitation to assess transcriptional regulation

• In vivo validation methods:

  • Orthotopic xenograft models with isoform-modified cells

  • Circulating tumor cell analysis for EMT phenotypes

  • Metastasis quantification in animal models

  • Patient sample correlation studies

• Therapeutic implication assessment:

  • EMT inhibitor screening in PRKCSH-modulated systems

  • Combination approaches targeting both PRKCSH and EMT pathways

  • Drug resistance evaluation in cells with altered PRKCSH isoform expression

This integrated approach enables comprehensive characterization of how PRKCSH isoforms mechanistically influence the EMT process, particularly in lung cancer cells where this relationship has been documented .

How should researchers design experiments to investigate PRKCSH's association with tumor progression markers?

The significant correlation between PRKCSH expression and poor clinical outcomes across multiple cancer types necessitates rigorous experimental designs to elucidate its relationship with tumor progression markers . Researchers should implement the following methodological framework:

• Clinical correlation studies:

  • Tissue microarray analysis across tumor stages and grades

  • Multi-marker immunohistochemical panels including PRKCSH

  • Quantitative image analysis for precise expression measurement

  • Patient outcome correlation with standardized statistical methods

• Molecular mechanism investigation:

  • Genetic manipulation of PRKCSH in cell line models:

    • Stable knockout/knockdown cell lines

    • Inducible expression systems

    • Rescue experiments with wild-type vs. mutant PRKCSH

  • Functional assays measuring:

    • Proliferation (cell counting, MTT/XTT assays, EdU incorporation)

    • Apoptosis resistance (Annexin V, caspase activity, TUNEL)

    • Angiogenesis (HUVEC tube formation, VEGF secretion)

    • Invasion (basement membrane penetration assays)

• Pathway analysis approaches:

  • Phospho-proteomic profiling to identify activated signaling

  • Gene expression analysis following PRKCSH modulation

  • ChIP-seq to identify transcriptional targets

  • Interactome mapping via BioID or proximity labeling

• In vivo model systems:

  • Genetically engineered mouse models with tissue-specific PRKCSH manipulation

  • Patient-derived xenografts with varied PRKCSH expression

  • Metastasis tracking using bioluminescence imaging

• Multi-omics integration strategies:

  • Correlative analysis across:

    • Genomic alterations (copy number, mutations)

    • Transcriptomic profiles (RNA-seq)

    • Proteomic landscapes (MS-based proteomics)

    • Glycomic patterns (glycan profiling)

This comprehensive approach leverages findings from pan-cancer studies showing PRKCSH overexpression in most tumor types and its association with advanced disease stages in eleven tumor types . The data generated would provide mechanistic insights into how PRKCSH contributes to tumor progression and potentially identify novel intervention points.

What are the emerging approaches for targeting PRKCSH in precision medicine?

As PRKCSH emerges as a potential therapeutic target, several innovative approaches are being developed for its precise targeting in personalized medicine contexts:

• Small molecule development strategies:

  • Structure-based design targeting functional domains

  • High-throughput screening of compound libraries

  • Connectivity Map (Cmap) analysis has predicted 24 potential therapeutic small molecules effective in over four cancer types

  • Repurposing of glycosylation pathway inhibitors

• Antibody-based therapeutic approaches:

  • Blocking antibodies against functionally critical domains

  • Antibody-drug conjugates for targeted delivery

  • Bispecific antibodies linking PRKCSH to immune effectors

  • Intrabodies targeting intracellular PRKCSH functions

• RNA interference and gene editing:

  • Targeted siRNA delivery systems

  • CRISPR-Cas9 approaches for genomic modification

  • Antisense oligonucleotides targeting specific splice variants

  • mRNA degradation through N6-methyladenosine (m6A) writers

• Biomarker development framework:

  • PRKCSH expression as predictive marker for therapy response

  • Methylation status as epigenetic biomarker (significant negative correlation with expression in 27 tumor types)

  • Combined assessment with TMB and MSI status

  • Liquid biopsy approaches for non-invasive monitoring

• Combination therapy rationales:

  • Synergy with immunotherapy (checkpoint inhibitors)

  • Integration with standard chemotherapy regimens

  • Combination with ER stress modulators

  • Sequential therapy designs based on molecular evolution

These emerging approaches leverage the finding that PRKCSH serves as a potential oncogene with prognostic significance across multiple cancer types . The significant correlations with established biomarkers like TMB and MSI further support its potential role in precision medicine strategies targeting cancer-specific vulnerabilities.

What methodological advances are needed to better understand PRKCSH's role in N-glycosylation quality control?

Despite PRKCSH's established function as the beta subunit of Glucosidase II in N-glycosylation quality control, several methodological challenges remain in fully elucidating its mechanistic contributions. Future research should address these gaps through:

• Advanced structural biology approaches:

  • Cryo-EM studies of the complete Glucosidase II complex

  • Hydrogen-deuterium exchange mass spectrometry for conformational dynamics

  • Single-molecule FRET to monitor interaction kinetics

  • In-cell NMR for physiologically relevant structural information

• Glycoprotein trafficking visualization:

  • Live-cell super-resolution microscopy of glycoprotein movement

  • Correlative light and electron microscopy for ultrastructural context

  • Engineered glycoprotein sensors with spectral shifts upon folding

  • Quantitative pulse-chase imaging of glycoprotein maturation

• Systems-level glycosylation analysis:

  • Glycoproteomics with site-specific quantification

  • Integrated glycomics-proteomics-transcriptomics

  • Computational modeling of ER quality control networks

  • AI-assisted glycosylation pattern recognition

• Physiologically relevant model systems:

  • Organ-on-chip technologies incorporating glycosylation monitoring

  • Patient-derived organoids with PRKCSH variants

  • Humanized mouse models with tissue-specific PRKCSH modulation

  • CRISPR-engineered isogenic cell lines with domain-specific mutations

• Temporal dynamics investigation:

  • Optogenetic control of PRKCSH activity

  • Fast-acting degron systems for acute protein depletion

  • Microfluidic systems for precise temporal perturbation

  • Single-cell temporal profiling of glycosylation states

These methodological advances would help resolve the complex interplay between PRKCSH, its binding partners, and substrate glycoproteins in the highly regulated environment of the ER quality control system . Understanding these mechanisms is particularly important given PRKCSH's role in helping cancer cells manage increased protein demand and ER stress .